News Updates
GIBH has established a cooperative partnership with the Center for World Health and Medicine, Saint Louis University
Posted: Jul 14, 2011
Recently GIBH and the Center for World Health and Medicine, Saint Louis University have signed a consortium master agreement to develop Plasmodium plasmepsin V (PMV) inhibitors. The principal objective of this collaborative research project is to develop safe, effective, and affordable inhibitors of PMV as a human therapeutic treatment for Malaria.
Malaria is a devastating mosquito-borne infectious disease caused by a parasite of the genus Plasmodium. It is widespread in tropical and subtropical regions, including Central and South America, Asia, and Africa. Each year there are approximately 350-500 million cases of malaria, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa, where ninety percent of malaria-related deaths occur. Although there are a number of drugs used to treat malaria, resistance to these drugs is becoming more widespread.
This collaboration, which looks to exploit newly discovered mechanisms, has centralized a strong expertise and resources necessary to successfully drive this project to validate the target pharmacologically and ultimately identify a clinical candidate for malaria.
Founded in 1818, Saint Louis University is the oldest university west of the Mississippi and the second oldest Jesuit University in the United States.
Recently GIBH and the Center for World Health and Medicine, Saint Louis University have signed a consortium master agreement to develop Plasmodium plasmepsin V (PMV) inhibitors. The principal objective of this collaborative research project is to develop safe, effective, and affordable inhibitors of PMV as a human therapeutic treatment for Malaria.
Malaria is a devastating mosquito-borne infectious disease caused by a parasite of the genus Plasmodium. It is widespread in tropical and subtropical regions, including Central and South America, Asia, and Africa. Each year there are approximately 350-500 million cases of malaria, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa, where ninety percent of malaria-related deaths occur. Although there are a number of drugs used to treat malaria, resistance to these drugs is becoming more widespread.
This collaboration, which looks to exploit newly discovered mechanisms, has centralized a strong expertise and resources necessary to successfully drive this project to validate the target pharmacologically and ultimately identify a clinical candidate for malaria.
Founded in 1818, Saint Louis University is the oldest university west of the Mississippi and the second oldest Jesuit University in the United States.
http://www.cwhm.org/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=5&cntnt01returnid=77
Malaria is a devastating mosquito-borne infectious disease caused by a parasite of the genus Plasmodium. It is widespread in tropical and subtropical regions, including Central and South America, Asia, and Africa. Each year there are approximately 350-500 million cases of malaria, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa, where ninety percent of malaria-related deaths occur. Although there are a number of drugs used to treat malaria, resistance to these drugs is becoming more widespread.
This collaboration, which looks to exploit newly discovered mechanisms, has centralized a strong expertise and resources necessary to successfully drive this project to validate the target pharmacologically and ultimately identify a clinical candidate for malaria.
Founded in 1818, Saint Louis University is the oldest university west of the Mississippi and the second oldest Jesuit University in the United States.
Recently GIBH and the Center for World Health and Medicine, Saint Louis University have signed a consortium master agreement to develop Plasmodium plasmepsin V (PMV) inhibitors. The principal objective of this collaborative research project is to develop safe, effective, and affordable inhibitors of PMV as a human therapeutic treatment for Malaria.
Malaria is a devastating mosquito-borne infectious disease caused by a parasite of the genus Plasmodium. It is widespread in tropical and subtropical regions, including Central and South America, Asia, and Africa. Each year there are approximately 350-500 million cases of malaria, killing between one and three million people, the majority of whom are young children in sub-Saharan Africa, where ninety percent of malaria-related deaths occur. Although there are a number of drugs used to treat malaria, resistance to these drugs is becoming more widespread.
This collaboration, which looks to exploit newly discovered mechanisms, has centralized a strong expertise and resources necessary to successfully drive this project to validate the target pharmacologically and ultimately identify a clinical candidate for malaria.
Founded in 1818, Saint Louis University is the oldest university west of the Mississippi and the second oldest Jesuit University in the United States.
http://www.cwhm.org/index.php?mact=News,cntnt01,detail,0&cntnt01articleid=5&cntnt01returnid=77
Attachment Download：